Evidence map›Paper›PMID 40962858›Full record

ArticleOncogene2025

NMRK2 leads to the depletion of CD8

Yi Chen, Xuwentai Liu, Mengmeng Wu, Xiang Dong, Wenliang Ma, Fan Feng, Yibing Ding, Ping Dong, Weidong Ding, Luqing Zhang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yi Chen *Department of Urology, Nanjing Drum Tower Hospital, State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Xuwentai Liu *Department of Urology, Nanjing Drum Tower Hospital, State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Mengmeng WuJiangsu Key Laboratory of Molecular Medicine, Division of Anatomy and Histo-embryology, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Xiang DongDepartment of Urology, Nanjing Drum Tower Hospital, State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Wenliang MaDepartment of Thoracic Surgery, Affiliated Drum Tower Hospital of Medical School of Nanjing University, Nanjing, Jiangsu, China.
Fan FengDepartment of Urology, Nanjing Drum Tower Hospital, State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Yibing DingTranslational Medicine Core Facilities, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Ping DongJiangsu Key Laboratory of Molecular Medicine, Division of Anatomy and Histo-embryology, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Weidong DingJiangsu Key Laboratory of Molecular Medicine, Division of Anatomy and Histo-embryology, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Luqing ZhangJiangsu Key Laboratory of Molecular Medicine, Division of Anatomy and Histo-embryology, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Ning LiuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. LNnjubg@163.com.
Weidong GanDepartment of Urology, Nanjing Drum Tower Hospital, State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China. gwd@nju.edu.cn.ORCID 0000-0002-7283-7294
Dongmei LiDepartment of Urology, Nanjing Drum Tower Hospital, State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China. lidm@nju.edu.cn.ORCID 0000-0003-3819-355X

Funding

Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation) BK20221444
6 · The paper itself

Abstract

PRCC-TFE3 rearrangement renal cell carcinoma (rRCC) is an independent subtype of rRCC caused by chromosomal translocation and rearrangement. Previous studies have revealed that nicotinamide riboside kinase 2 (NMRK2), which is transcriptionally upregulated by PRCC-TFE3 fusion protein, as a pivotal molecule in the energy metabolism remodeling of PRCC-TFE3 rRCC. However, the molecular mechanism by which NMRK2-mediated enhancement of nicotinamide adenine dinucleotide (NAD

Indexed as

ADP-ribosyl Cyclase 1Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, Renal CellCD8-Positive T-LymphocytesKidney NeoplasmsMembrane GlycoproteinsNADSirtuin 1AnimalsCell Line, TumorHumansMiceSignal TransductionADP-ribosyl Cyclase 1Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCD38 protein, humanMembrane GlycoproteinsNADSIRT1 protein, humanSirtuin 1TFE3 protein, human

Identifiers

PMID40962858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.